A new study suggests a model of gait training may be applicable to multiple sclerosis rehabilitation clinics with virtual reality systems of various levels of sophistication.
Findings from a large real-world multiple sclerosis dataset argue for continued use of brain and thalamic volume as clinical trial outcomes — and further work to apply them in clinical practice.
Use of highly effective disease-modifying therapies at leading multiple sclerosis centers hasn’t increased much over the past dozen years, an observational study reveals.
Response to the drug in progressive forms of multiple sclerosis appears to be driven by effects in primary, rather than secondary, progressive disease. Differences in the pace of atrophy progression may explain.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A large survey of patients with MS finds that risk tolerance varies widely but tends to be highest in men, younger patients and those with greater disability.
Neurologist Robert Fox, MD, is the 2018 Sones Innovation Award honoree for leading pioneering advancements in brain imaging and treatment of the challenging progressive form of multiple sclerosis.
A new study shows that neuroperformance testing of patients using a suite of iPad apps at every outpatient visit is achievable and promises real value in informing clinical practice.
On the eve of ACTRIMS Forum 2019, Dr. Jeffrey Cohen explains the professional society’s unique mission and how it aims to keep paralleling the fast-evolving MS subspecialty it serves.
The discovery of a new MS subtype using Cleveland Clinic’s rapid brain donation program suggests that the axon itself, rather than myelin, may be the primary site of injury in the disease.
Disease-modifying therapy for multiple sclerosis is not without risks. Since its benefits may wane as immune function diminishes with age, discontinuation is tempting. A new study gives supportive reassurance.